Biotic acts of antibiotics, Frontiers in Microbiology, vol.4, 2013. ,
DOI : 10.3389/fmicb.2013.00241
Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?, Journal of Antimicrobial Chemotherapy, vol.55, issue.1, pp.10-21, 2005. ,
DOI : 10.1093/jac/dkh519
Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro, Journal of Antimicrobial Chemotherapy, vol.60, issue.5, pp.1155-1158, 2007. ,
DOI : 10.1093/jac/dkm338
Long-Term Azithromycin Therapy in Cystic Fibrosis Patients: A Study on Drug Levels and Sputum Properties, Canadian Respiratory Journal, vol.11, issue.2, pp.151-155, 2004. ,
DOI : 10.1155/2004/747841
Evolution of a new drug formulation: the rationale for high-dose, short-course therapy with azithromycin, International Journal of Antimicrobial Agents, vol.26, issue.05, pp.143-147, 2005. ,
DOI : 10.1016/S0924-8579(05)80320-6
Increased Susceptibility of Pseudomonas aeruginosa to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of oprM and Increased Outer-Membrane Permeability, Clinical Infectious Diseases, vol.55, issue.4, pp.534-542, 2012. ,
DOI : 10.1093/cid/cis473
The biology and future prospects of antivirulence therapies, Nature Reviews Microbiology, vol.92, issue.1, pp.17-27, 2007. ,
DOI : 10.1038/nrmicro1818
Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial, Thorax, vol.61, issue.10, pp.895-902, 2005. ,
DOI : 10.1136/thx.2005.057950
Global regulatory pathways and cross-talk control Pseudomonas aeruginosa environmental lifestyle and virulence phenotype, Curr. Issues Mol. Biol, vol.14, pp.47-70, 2012. ,
The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections, Drugs, vol.111, issue.3, pp.351-368, 2007. ,
DOI : 10.2165/00003495-200767030-00003
Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial, The Lancet, vol.360, issue.9338, pp.978-984, 2002. ,
DOI : 10.1016/S0140-6736(02)11081-6
Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin, Journal of Antimicrobial Chemotherapy, vol.52, issue.4, pp.598-604, 2003. ,
DOI : 10.1093/jac/dkg397
Fighting bacterial infections???Future treatment options, Drug Resistance Updates, vol.14, issue.2, pp.125-139, 2011. ,
DOI : 10.1016/j.drup.2011.02.001
Paradoxical Aspects of Rapamycin Immunobiology in Transplantation, American Journal of Transplantation, vol.460, issue.4, 2011. ,
DOI : 10.1111/j.1600-6143.2011.03473.x
A retrospective analysis of the impact of azithromycin maintenance therapy on adults attending a UK cystic fibrosis clinic, Journal of Cystic Fibrosis, vol.12, issue.1, pp.49-53, 2013. ,
DOI : 10.1016/j.jcf.2012.05.010
The pharmacokinetics of azithromycin in human serum and tissues, Journal of Antimicrobial Chemotherapy, vol.25, issue.suppl A, pp.73-82, 1990. ,
DOI : 10.1093/jac/25.suppl_A.73
Immunomodulatory therapies for sepsis: unexpected effects with macrolides, International Journal of Antimicrobial Agents, vol.32, pp.39-43, 2008. ,
DOI : 10.1016/j.ijantimicag.2008.06.004
Azithromycin Retards Pseudomonas aeruginosa Biofilm Formation, Journal of Clinical Microbiology, vol.42, issue.12, pp.5842-5845, 2004. ,
DOI : 10.1128/JCM.42.12.5842-5845.2004
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution., Antimicrobial Agents and Chemotherapy, vol.31, issue.12, pp.1948-1954, 1948. ,
DOI : 10.1128/AAC.31.12.1948
Recycling of Peptidyl-tRNAs by Peptidyl-tRNA Hydrolase Counteracts Azithromycin-Mediated Effects on Pseudomonas aeruginosa, Antimicrobial Agents and Chemotherapy, vol.57, issue.4, pp.1617-1624, 2013. ,
DOI : 10.1128/AAC.02582-12
U.S. Outpatient Antibiotic Prescribing, 2010, New England Journal of Medicine, vol.368, issue.15, pp.1461-1462, 2010. ,
DOI : 10.1056/NEJMc1212055
Azithromycin Improves Macrophage Phagocytic Function and Expression of Mannose Receptor in Chronic Obstructive Pulmonary Disease, American Journal of Respiratory and Critical Care Medicine, vol.178, issue.2, pp.139-148, 1128. ,
DOI : 10.1164/rccm.200711-1666OC
The Influence of Azithromycin on the Biofilm Formation of <i>Pseudomonas aeruginosa</i> in vitro, Chemotherapy, vol.42, issue.3, pp.186-191, 1996. ,
DOI : 10.1159/000239440
Azithromycin Exhibits Bactericidal Effects on Pseudomonas aeruginosa through Interaction with the Outer Membrane, Antimicrobial Agents and Chemotherapy, vol.49, issue.4, pp.1377-1380, 2005. ,
DOI : 10.1128/AAC.49.4.1377-1380.2005
Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity, Proceedings of the National Academy of Sciences, vol.110, issue.18, pp.7458-7463, 2013. ,
DOI : 10.1073/pnas.1222706110
The use of macrolide antibiotic substances in the treatment of asthma, Journal of Allergy, vol.45, issue.3, pp.146-162, 1970. ,
DOI : 10.1016/0021-8707(70)90124-3
Long-term azithromycin may improve lung function in children with cystic fibrosis, The Lancet, vol.351, issue.9100, pp.140-673678360, 1998. ,
DOI : 10.1016/S0140-6736(05)78360-4
A low concentration of azithromycin inhibits the mRNA expression of N-acyl homoserine lactone synthesis enzymes, upstream of lasI or rhlI, in Pseudomonas aeruginosa, Pulmonary Pharmacology & Therapeutics, vol.22, issue.6, pp.483-486, 2009. ,
DOI : 10.1016/j.pupt.2009.04.004
Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications, Clinical Microbiology Reviews, vol.23, issue.3, pp.590-615, 2010. ,
DOI : 10.1128/CMR.00078-09
by erythromycin, Journal of Antimicrobial Chemotherapy, vol.27, issue.3, pp.273-284, 1991. ,
DOI : 10.1093/jac/27.3.273
Ribosome Protection Prevents Azithromycin-Mediated Quorum-Sensing Modulation and Stationary-Phase Killing of Pseudomonas aeruginosa, Antimicrobial Agents and Chemotherapy, vol.51, issue.12, pp.4243-4248, 2007. ,
DOI : 10.1128/AAC.00613-07
Drug repurposing: a better approach for infectious disease drug discovery?, Current Opinion in Immunology, vol.25, issue.5, pp.588-592, 2013. ,
DOI : 10.1016/j.coi.2013.08.004
Azithromycin reduces spontaneous and induced inflammation in ??F508 cystic fibrosis mice, Respiratory Research, vol.174, issue.1, pp.134-144, 2006. ,
DOI : 10.1093/infdis/174.5.994
Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm, BMC Microbiology, vol.12, issue.1, pp.196-206, 2012. ,
DOI : 10.1093/jac/dki338
A Clinical Pharmacokinetic Study of Tacrolimus and Sirolimus Combination Immunosuppression Comparing Simultaneous to Separated Administration, Therapeutic Drug Monitoring, vol.24, issue.3, pp.346-350, 2002. ,
DOI : 10.1097/00007691-200206000-00004
Immunization with 3-oxododecanoyl-L-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection, Journal of Medical Microbiology, vol.55, issue.10, pp.1381-1387, 2006. ,
DOI : 10.1099/jmm.0.46658-0
virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics, Journal of Antimicrobial Chemotherapy, vol.31, issue.5, pp.681-688, 1993. ,
DOI : 10.1093/jac/31.5.681
Inhibition of motility ofPseudomonas aeruginosa andProteus mirabilis by subinhibitory concentrations of azithromycin, European Journal of Clinical Microbiology & Infectious Diseases, vol.12, issue.Supplement 3, pp.469-471, 1007. ,
DOI : 10.1007/BF01961867
Roles of MexXY- and MexAB-multidrug efflux pumps in intrinsic multidrug resistance of Pseudomonas aeruginosa PAO1., The Journal of General and Applied Microbiology, vol.47, issue.1, pp.27-32, 2001. ,
DOI : 10.2323/jgam.47.27
Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa, Clinical Microbiology and Infection, vol.3, issue.4, pp.432-439, 1997. ,
DOI : 10.1111/j.1469-0691.1997.tb00279.x
Quorum-Sensing Antagonistic Activities of Azithromycin in Pseudomonas aeruginosa PAO1: a Global Approach, Antimicrobial Agents and Chemotherapy, vol.50, issue.5, pp.1680-1688, 2006. ,
DOI : 10.1128/AAC.50.5.1680-1688.2006
Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects onPseudomonas aeruginosa phenotypes, Pediatric Pulmonology, vol.36, issue.6, pp.533-541, 2007. ,
DOI : 10.1002/ppul.20620
Influence of adjunct azithromycin on the mortality of experimental Pseudomonas aeruginosa sepsis, International Journal of Antimicrobial Agents, vol.8, issue.4, pp.239-241, 1997. ,
DOI : 10.1016/S0924-8579(97)00017-4
Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model, Antimicrob. Agents Chemother, vol.43, pp.3033-3035, 1999. ,
A journey across the sequential development of macrolides and ketolides related to erythromycin, Tetrahedron, vol.62, issue.14, pp.3171-3200, 2006. ,
DOI : 10.1016/j.tet.2005.11.064
Azithromycin Inhibits Expression of the GacA-Dependent Small RNAs RsmY and RsmZ in Pseudomonas aeruginosa, Antimicrobial Agents and Chemotherapy, vol.55, issue.7, pp.3399-3405, 2011. ,
DOI : 10.1128/AAC.01801-10
The bacterial ribosome as a target for antibiotics Anti-virulence strategies to combat bacteria-mediated disease, Nat. Rev. Microbiol. Nat. Rev. Drug Discov, vol.3, issue.9, pp.870-881, 2005. ,
Effect of Azithromycin on Systemic Markers of Inflammation in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa, Chest, vol.142, issue.5, pp.1259-1266, 1378. ,
DOI : 10.1378/chest.12-0628
Macrolides: structures and microbial targets, International Journal of Antimicrobial Agents, vol.18, issue.01, pp.3-10, 2001. ,
DOI : 10.1016/S0924-8579(01)00401-0
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gramnegative organisms, Antimicrob. Agents Chemother, vol.31, 1939. ,
Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With <emph type="ital">Pseudomonas aeruginosa</emph><subtitle>A Randomized Controlled Trial</subtitle>, JAMA, vol.303, issue.17, pp.1707-1715, 2010. ,
DOI : 10.1001/jama.2010.563
Azithromycin in Patients With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa, JAMA, vol.290, issue.13, pp.1749-1756, 2003. ,
DOI : 10.1001/jama.290.13.1749
The influence of mTOR on T helper cell differentiation and dendritic cell function, European Journal of Immunology, vol.13, issue.8, pp.2137-2141, 2011. ,
DOI : 10.1002/eji.201141523
Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis, Journal of Antimicrobial Chemotherapy, vol.54, issue.1, pp.21-28, 2004. ,
DOI : 10.1093/jac/dkh309
Effects of Antibiotics on Quorum Sensing in Pseudomonas aeruginosa, Antimicrobial Agents and Chemotherapy, vol.52, issue.10, pp.3648-3663, 1128. ,
DOI : 10.1128/AAC.01230-07
Macrolide antibiotics for cystic fibrosis, Cochrane Database Syst. Rev, 2004. ,
Reduced Release of Pneumolysin by Streptococcus pneumoniae In Vitro and In Vivo after Treatment with Nonbacteriolytic Antibiotics in Comparison to Ceftriaxone, Antimicrobial Agents and Chemotherapy, vol.47, issue.8, pp.2649-2654, 2003. ,
DOI : 10.1128/AAC.47.8.2649-2654.2003
Pathogen- and Host-Directed Anti-Inflammatory Activities of Macrolide Antibiotics, Mediators of Inflammation, vol.5, issue.4, pp.5842-5862, 2012. ,
DOI : 10.4065/mcp.2010.0392
Macrolide Antibiotic-Mediated Downregulation of MexAB-OprM Efflux Pump Expression in Pseudomonas aeruginosa, Antimicrobial Agents and Chemotherapy, vol.52, issue.11, pp.4141-4144, 2008. ,
DOI : 10.1128/AAC.00511-08
Azithromycin Inhibits Quorum Sensing in Pseudomonas aeruginosa, Antimicrobial Agents and Chemotherapy, vol.45, issue.6, 1930. ,
DOI : 10.1128/AAC.45.6.1930-1933.2001
Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa., Antimicrobial Agents and Chemotherapy, vol.37, issue.4, pp.675-680, 1993. ,
DOI : 10.1128/AAC.37.4.675
grown in the presence of sub-MICs of macrolide antibiotics and their relation to enhanced serum sensitivity, Journal of Antimicrobial Chemotherapy, vol.34, issue.6, pp.931-942, 1994. ,
DOI : 10.1093/jac/34.6.931
Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin, Antimicrob. Agents Chemother, vol.40, pp.2271-2275, 1996. ,
Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice, Inflammation Research, vol.178, issue.8, pp.491-501, 2009. ,
DOI : 10.1007/s00011-009-0015-9
Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial, Intensive Care Medicine, vol.55, issue.Suppl 1, pp.1118-1125, 2012. ,
DOI : 10.1007/s00134-012-2559-3
Infection, American Journal of Respiratory and Critical Care Medicine, vol.184, issue.3, pp.345-354, 2011. ,
DOI : 10.1164/rccm.201103-0374OC